Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDivislaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Idea Cellular, Divis Labs, Glenmark: Manish Hathiramani

      Manish Hathiramani of Deen Dayal Investments recommends buying Idea Cellular, Divis Laboratories and Glenmark Pharma.

    • Sell SBI; buy Divis Labs: Sameet Chavan

      Sameet Chavan of Angel Broking is of the view that one can sell State Bank of India and advises buying Divis Laboratories.

    • Divis Lab may hit Rs 1885: Yogesh Mehta

      According to Yogesh Mehta of Motilal Oswal Securities, Divis Laboratories may touch Rs 1885.

    • Divis Laboratories may test Rs 1900: Nooresh Merani

      Nooresh Merani of Analyse India is of the view that Divis Laboratories may test Rs 1900 over the next few weeks.

    • Buy Divis lab, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Divis Labs.

    • Hold Divis Laboratories: Amit Gupta

      Amit Gupta of ICICIdirect is of the view that one may go long in Divis Laboratories and advises holding the stock.

    • Prefer Divis Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer Divis Laboratories.

    • Divis Laboratories may test Rs 1800: Kunal Saraogi

      Kunal Saraogi of Equityrush feels that Divis Laboratories may test Rs 1800.

    • Divis Laboratories may touch Rs 1776, says Rajat Bose

      Rajat Bose of rajatbose.com is of the view that Divis Laboratories may touch Rs 1776.

    • Buy Divis Labs, UPL, NTPC: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends buying Divis Labs, UPL and NTPC.

    • Buy Transport Corp, Divis Labs, Tata Coffee: AK Prabharkar

      AK Prabharkar, Independent Advisor recommends buying Biocon for a target price of Rs 492 and Tata Coffee for a target price of Rs 1044.

    • Bull's Eye: Buy Divis Labs, Tata Coffee; short YES Bank

      Meghna V Malkan of malkansview.com recommends shorting YES Bank for a target price of Rs 655 and advises buying Jubilant Foodworks for a target price of Rs 1475.

    • Buy Divis Labs: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends buying Divis Laboratories.

    • Buy Hero Motocorp, Divis Labs, Ambuja Cements: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Hero Motocorp, Divis Laboratories and Ambuja Cements.

    • Buy Divis Laboratories, advises Sudarahan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Divis Laboratories.

    • Buy Divis Laboratories, says Hemant Thukral

      According to Hemant Thukral of Aditya Birla Money, one may buy Divis Laboratories. It may retest Rs 1,870-1,880.

    • Prefer Axis Bank, Wipro, Divis Labs: Phani Sekhar

      P Phani Sekhar, Fund Manager, PMS at Angel Broking is of the view that one may prefer Divis Labs, Wipro, Hindustan Media Ventures, Indiabulls Housing Finance and LIC Housing Finance.

    • Prefer Divis Laboratories, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer Divis Laboratories.

    • Super Six stocks you can bet on September 3

      Hemen Kapadia of KR Choksey Securities advises selling Mahindra and Mahindra with a target of Rs 1376 and buying Divis Lab with a target of Rs 1619.

    • Buy India Cements, Titan Company, Divis Labs: Vishal Malkan

      Vishal Malkan of malkansview.com recommends buying Divis Laboratories with a target of Rs 1625 and Titan Company with a target of Rs 395.

    • Bull's Eye: Buy Kaveri Seed, Tata Chemicals, Greaves Cotton

      Vishal B Malkan, malkansview.com advises buying Tata Chemicals for a target price of Rs 400 and India Cements for a target price of Rs 115.

    • Bull's Eye: JP Associates, Tech Mahindra, Aurobindo Pharma

      Vishal Jajoo, Nirmal Bang Securities advises buying Kopran for a target price of Rs 65.50 and Jaiprakash Associates for a target price of Rs 55.75.

    • Buy Divis Labs, Canara Bank, Corormandel Intl: AK Prabhakar

      AK Prabhakar, independent advisor is of the view that one can buy Coromandel International with a long term target of Rs 400 and feels that Mirza International may test Rs 40-50.

    • Buy Divis Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Divis Laboratories.

    • Bull's Eye: Buy FDC, CCL Products, Canara Bank, HCL Info

      Nooresh Mirani of Analyse India advises buying FDC for a target price of Rs 170 and HCL Infosystems for a target price of Rs 95.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347